Literature DB >> 10535753

Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier.

R Zhao1, F Gao, I D Goldman.   

Abstract

A phenylalanine substitution for serine in the reduced folate carrier at residue 309 (RFC1-S309F) was identified in a methotrexate (MTX)-resistant cell line selected with 5-formyltetrahydrofolate (5-CHO-THF) as the sole folate source. The transport characteristics of the mutated carrier were studied by transfection into the MTXrA line, which lacks endogenous RFC1 function. The level of expression of carrier in the cell lines studied was determined by specific surface binding of 5-methyltetrahydrofolate (5-CH3-THF). Influx of 5-CH3-THF and 5-CHO-THF mediated by RFC1-S309F was 20- and 7-fold greater than that of MTX, respectively. Consistent with the influx difference between 5-CHO-THF and MTX, the growth requirement (EC50) for 5-CHO-THF in MTXrA-S309F cells was decreased by a factor of 9, while the MTX IC50 was reduced by a factor of only approximately 2 as compared with the recipient MTXrA cells. The decrease in 5-CH3-THF influx mediated by the mutated carrier was attributed to a decrease in the mobility of the 5-CH3-THF-carrier complex, since the influx Kt was essentially unchanged. However, the reduction in 5-CHO-THF and MTX influx was attributed to decreases in both carrier affinity and Vmax, although the decline in the MTX influx Vmax appeared to be much greater than for 5-CHO-THF. The inhibitory effect of chloride on 5-CHO-THF influx observed for L1210 cells was eliminated in the MTXrA-S309F line. This study represents another example of a single mutation in RFC1 that markedly impairs MTX influx but partially preserves transport of reduced folates when cells are selected with 5-CHO-THF as the available folate substrate. The data indicate that residues in the predicted eighth transmembrane domain of RFC1 can play an important role in the selectivity of folate binding and the mobility of the carrier-substrate complex.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10535753     DOI: 10.1016/s0006-2952(99)00257-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter.

Authors:  Larry H Matherly; Zhanjun Hou
Journal:  Vitam Horm       Date:  2008       Impact factor: 3.421

Review 2.  The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.

Authors:  Larry H Matherly; Mike R Wilson; Zhanjun Hou
Journal:  Drug Metab Dispos       Date:  2014-01-06       Impact factor: 3.922

3.  Substrate-specific binding and conformational changes involving Ser313 and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking.

Authors:  Zhanjun Hou; Jianmei Wu; Jun Ye; Christina Cherian; Larry H Matherly
Journal:  Biochem J       Date:  2010-09-01       Impact factor: 3.857

Review 4.  Biology of the major facilitative folate transporters SLC19A1 and SLC46A1.

Authors:  Zhanjun Hou; Larry H Matherly
Journal:  Curr Top Membr       Date:  2014       Impact factor: 3.049

5.  Role of lysine 411 in substrate carboxyl group binding to the human reduced folate carrier, as determined by site-directed mutagenesis and affinity inhibition.

Authors:  Yijun Deng; Zhanjun Hou; Lei Wang; Christina Cherian; Jianmei Wu; Aleem Gangjee; Larry H Matherly
Journal:  Mol Pharmacol       Date:  2008-01-08       Impact factor: 4.436

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.